Home / Market News / $CMPT
benzinga Corporate Catalyst Impact 75/100 ● positive

Compass Therapeutics shares are trading higher after Piper Sandler raised its price target on the stock from $4 to $6.

Aug 7, 2026, 6:28 PM UTC · Primary ticker $CMPT

Compass Therapeutics shares are experiencing a significant positive movement due to a substantial price target increase from Piper Sandler. This upgrade signals increased analyst confidence and could attract further investor interest, driving the stock higher in the short term.

The Piper Sandler price target increase from $4 to $6 represents a 50% jump, indicating a strong vote of confidence in Compass Therapeutics' future prospects, likely based on pipeline developments or clinical trial results. This positive analyst sentiment often acts as a significant catalyst, attracting new investors and potentially triggering short covering. While the immediate impact is positive for CMPT, the sustainability of this rally depends on fundamental developments and broader market sentiment towards the biotechnology sector. Investors should monitor future news from Compass Therapeutics and any further analyst revisions.

$CMPT positive Direct beneficiary of price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.